View full meeting coverage »

Eyetube Meeting Coverage:

2017 American Academy of Ophthalmology



Your 25-second video preview has ended.

to continue watching, please Log In or Register:

Log in / Register

Suprachoroidal Steroids for DME

  Channels: Retina | Posted 11/17/2017

Charles Wykoff, MD, PhD, reviews the results of the 6-month prospective phase 1/2 HULK study evaluating the use of preservative-free suprachoroidal triamcinolone acetonide in patients with DME. Dr. Wykoff notes the efficacy of intravitreal anti-VEGF therapy and corticosteroids in patients with DME and explains how the open-label, multicenter study expanded on this with suprachoroidal delivery of corticosteroids to 20 previously treated or treatment-naïve patients. Anatomic efficacy was demonstrated across all eyes, and visual acuity gains were also seen, largely driven by the treatment-naïve population.

HULK • suprachoroidal drug delivery

2 / 26 Series: 2017 American Academy of Ophthalmology

More Videos in this Series

View full meeting coverage (26 videos)
This program is not affiliated with the official program of AAO 2017.